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Drug - Induced
Respiratory Diseases
Vijayan V. K.
Drug-Inducedrespiratory diseases are becoming increasingly apparent,as more than 40 commonly used drugs are reported to cause pulmonary
parenchymal tissue injury(1,2). Drug -induced interstitial lung diseases can
be acute or chronic. Due to irreversible damage that may result from
drugs, treatment, for lethal diseases have to be withdrawn prematurely. It
is difficult to estimate the true incidence of drug induced pulmonary disease
because of the lack of specific markers, histologic findings or diagnostic
clinical features and also because of sporadic nature of many of these
reactions. Pharmacologic agents that may cause pulmonary parenchymal
injury can be classified into 2 group (Table 1). The first group involves
cytoloxic drugs and the second non cytoloxic drugs.
Mechanisms of drug - Induced puImonary disease
The lungs, the only organs in man, exposed to both internal and
external insults of various types has a number of homeostatic mechanisms
for maintaining a balance between damaging inflammatory reaction and
protective detoxification pathways. Drugs can affect any of these systems
resulting in pulmonary injury.
a) Oxidant- antioxidant system (1)
Drugs such as bleomycin, cyclophosphamide and amiodarone are capable
of producing reactive oxygen species (Oxidants) including the superoxide
anion (02), hydrogen peroxide (H202), the hydroxyl radical (OH), singlet
oxygen (1 02) and hypochlorous acid (HOCL). These oxidants can cause
autologous cytotoxicity, unless they are neutralised by antioxidants such as
superoxide dismutase (SOD), catalase, glutathione peroxidase, ceruloplasmin
and vitamin E. These antioxidant systems are present in virtually every
cell in the body. Over production of oxidants by the drugs, thus results
in an alteration of normal balance between oxidants and antioxidants,
resulting in pulmonary toxicity.
(b) Immunologic system (1,3-5)
Normal resident pulmonary cells are alveolar macrophages and
lymphocytes. Drugs can activate resident pulmonary cells, resulting in
attracting and activating peripheralinflammatory cells s u c h  a s
polymorphonuclear neutrophils (PMN), eosinophils and monocytes. These
activated cells liberate cytotoxic mediators. Experimental pulmonary fibrosis
induced by agents such as bleomycin, paraquat, N-nitroso-N-methylurethane
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etc. had shown that fibrosis of the alveolar wall first requires “injury” to
the alveolar wall, that is, damage to the existing cells and matrix, comprising
the lung parenchyma. Most of the injury results from the effector processes
of these cell types comprising alveolitis. Bronchoalveolar lavage (BAL) studies
(6-8) have demonstrated increased numbers of polymorphonuclear neutrophils
in patients with bleomycin, amiodarone, tocainide and phenytoin induced
pulmonary injury. A lymphocytic alveolitis in the BAL has been demonstrated
in lung damage due to bleomycin, methotrexate, gold salts, amiodarone and
nitrofurantoin. Lung eosinophilia have been reported in lung diseases due
to bleomycin, procarbazine, nitrofurantoin, gold etc. The relative potency of
the effector cells in regard to their ability to injure the alveolar wall is
probably, in descending order, neutrophils, alveolar macrophages, eosinophils
and lymphocytes. If the damage is sufficient such that normal alveolar
architecture cannot be reestablished, a secondary form of “repair”, ie.
replacement of the normal parenchyma by fibroblasts and their products,
takes over. Activated alveolar macrophages release chemoattractants for
neutrophils, leukotriene B4, interleukin 1, possibly interleukin 8, oxidants
and a variety of growth signals for mesenchymal cells including platelet -
derived growth factor (PDGF -B) fibronectin (FN), insulin like growth
factor 1 (IGF-1), transforming growth factor - beta (TGF-B), and Tumour
Necrosis Factor (TNF). Macrophage derived growth factors are shown in figure
1. Neutrophils release oxidants and potent proteinases such as collagenase
and neutrophil elastase. Eosinophils liberate oxidants, collagenase and a
variety of other agents such as major basic protein. Lymphocytes release
interleukin - 2, migration inhibition factor, monocyte chemotactic factor and
oxidants.
Fibronectin and alveolar macrophage derived growth factors (AMDGF),
the mediators released by alveolar macrophages play an important role in
fibrosis. Fibronectin (FN) recruits fibroblasts to the area of injury. Fibroblast
numbers expand as a result of mediators released by macrophages. FN
attaches fibroblasts to matrix which is made up of type I and type III
collagen. FN also acts as a “competence factor” to move fibroblasts through
the early phases of the Cl portion of the cell cycle (G1 is the earliest
phase of the cell proliferation cycle and precedes DNA synthesis). AMDGF
acts as a growth factor and in the presence of the “competence factor”
(FN) induces fibroblasts to move,through the late stages of GI and
prolifeate. This ultimately leads to fibrosis by replacement of normal
parenchymal cells and matrix by fibroblasts and fibroblast products. However,
macrophages are also capable of arresting fibrotic response by releasing
two cytokines, TNF- a and IL 1. They interact synergistically to augment
production of prostaglandins (PGE 2). PGE 2 is a powerful second messenger
that inhibits fibroblast proliferation. Pathogenesis of the fibrotic response
is given in Figure 2 (9, 10).
c. Proteolytic system (5).
Proteolytic enzymes, particularly elastase are produced  by
polymorphonuclear leukocytes and alveolar macrophages. There are a number
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of antiprotease systems in the lower respiratory tract, the most important
   being the alpha -1 - protease inhibitor. Reactive oxygen radicals released
by drugs such as bleomycin and cyclophosphamide can inactivate alpha -
1 - protease inhibitor resulting in enhanced activity of proteolytic enzymes.
d. Central Nervous System (CNS) (5)
A variety of CNS insults can cause neurogenic pulmonary oedema in
which there will be an increased capillary protein leak, This may suggest
that pulmonary capillary permeability may be, in part, controlled by the
central nervous system. Several drugs such as opiates, major tranquilizers,
salicylates and methotrexate may cause pulmonary oedema through their
effects on CNS. Presence of plentiful opiate receptors near the medullary
respiratory centre may support for neural influences in the development
of pulmonary oedema.
Risk factors (5) -
Risk factors predisposing to development of drug - induced pulmonary
disease are given in Table 2.
Clinical manifestations
Five distinct syndromes have been described.
1. Pneumonitis / fibrosis (1,5).
Drugs causing pneumonitis/fibrosis are shown in Table 3. Symptoms
begin insidiously, progressing over several weeks to months. Symptoms
include non-productive cough, dyspnoea on exertion, fatigue and malaise.
Significant weight loss can also occur. Bi-basilar end - expiratory crackles
can be heard on auscultation. Clubbing may be present. The chest radiograph
show bilateral reticular infiltrates. Occasionally chest radiograph is normal,
even in the presence of pulmonary symptoms and physiologic abnormalities.
Pulmonary function may show a restrictive ventilatory defect with a reduced
diffusing capacity. In general, most patients show some residual pulmonary
impairment despite appropriate treatment which include discontinuation of
the offending drug and institution of corticosteroids.
2. Hypersensitivity pneumonitis (1,5)
Drugs that cause hypersensitivity pneumonitis (HP) are shown in Table
4. HP is characterised by a subacute onset (within hours to days) of
dyspnoea, non-productive cough, chills, myalgia, fever and headache. Skin
rash may be present in 50% of patients. Auscultation may reveal crackles.
40% of patients will have peripheral eosinophilia. There may be signs of
hepatitis in a few cases. The chest radiograph shows diffuse acinar infiltrates,
pleural effusions are more common than those of pneumonitis. Pulmonary
function shows restriction with mildly reduced diffusing capacity. Lung biopsy
may show interstitial and airway eosinophilia with a paucity of fibrosis.
Virtually all patients, except those due to methotrexate, recover with few
residual pulmonary dysfunction. Treatment includes withdrawal of the drug
and institution of corticosteroids.
3. Non-Cardiogenic pulmonary oedema (1,5)
Symptoms occur acutely (over minutes to hours) and usually are
associated with overdose of the offending agents. Drugs that cause non -
cardiogenic pulmonary oedema are given in Table 5. Prognosis is variable
and generally better than other causes of non - cardiogenic pulmonary
oedema on removal of the offending agents.
4. Bronchiolitis obliterans (11)
This rare complications is usually due to three drugs namely, gold
salts, sulfasalazine and penicillamine. The underlying disease particularly
rheumatoid arthritis can cause similar pulmonary pathology in the absence
of drugs. Clinical symptoms include insidious onset of cough, dyspnoea and
weight loss. Chest radiographs may be normal or show localised infiltrate.
Pulmonary function shows an obstructive ventilatory defect. Histology shows
areas of inflammation surrounding bronchioles resulting in their obliteration.
In a proportion of patients especially due to sulfasalazine and penicillamine,
a significant alveolitis is present. Prognosis of this condition is poor. Despite
corticosteroid treatment and discontinuation of drugs, residual pulmonary
abnormalities will be persisting.
5. Pulmonary renal syndrome (5)
This is a rare complication of penicillamine treatment. Clinical
presentation includes hemoptysis, dyspnoea, pleuritic chest pain and uremia.
Chest radiographic abnormalities include diffuse acinar, reticular or confluent
large round densities. Lung histology shows pulmonary haemorrhage and
haemosiderin laden macrophages.Although similar to GoodPasture’s
Syndrome, there were no typical linear pattern of basement membrane
immunoglobulin deposition.Treatment includes immunosuppression and
plasmapheresis.
Screening tests (1,5)
1. Diffusing capacity for carbon monoxide (TLCO)
TLCO appears to be a sensitive, but relatively nonspecific test as a
predictor of drug-induced pneumonitisespecially in bleomycin or
amiodarone-induced pneumonitis. Patients who never develop clinical disease
had also shown a reduced TLCO.
2. Lung volumes
A redution in lung volumes is a restrictive ventilatory defect, appears
to be a specific test, but is not very sensitive. Patients with lung disease
have rarely shown normal lung volumes.
3. Computed tomographic scanning
The detection of fibrosis by CT scanning has been correlated with
lung volume measurements CT abnormalities were detected in patients
with normal chest radiographs. However, CT may not differentiate reversible
pneumonitis from irreversible fibrosis. CT may prove to be sensitive and
specific test in predicting development of drug-induced lung disease.
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4. Chest radiographs
Chest radiographs are both nonspecific and insensitive in detecting
pulmonary disease. An abnormal chest radiograph is a late manifestation
of drug-induced lung disease.
5. Gallium scanning
Positive gallium scans i.e. uptake of gallium-67 in area of acute
inflammation, in the absence of abnormal chest radiographs have been
reported in drug-induced lung diseases. However, there are no proper studies
to evaluate gallium scanning in drug-induced lung disease.
6. Soluble mediators
Soluble mediators such as serum angiotensin converting enzyme have
been described in all patients receiving bleomycin, but most of them do
not develop pulmonary fibrosis. This is a fertile field for future research
in drug-induced lung disease.
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Table 1
Pharmacologic agents that cause Pulmonary Parenchymal Injury
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Cytotoxic drugs Non Cytotoxic drugs
Antibiotics
Bleomycin
Mitomycin
Neocarzinostatin
Alkylating Agents
Busulfan
Cyclophosphamide
Chlorambucil
Melphalan
Nitrosoureas
Carmustine (BCNU)
Semustine (Methyl CCNU)
Lomystine (CCNU)
Chlorozotocin
Antimetabolites
Methotrexate
Azathioprine
Mercaptopurine
Cytosine arabinoside
Miscellaneous
Procarbazine
VM - 26
Vinblastine
Vindesine
13
Antibacterial agents
Nitrofurantoin
Amphotericin
Sulfasalazine
Analgesics
Aspirin
Opiates
Heroin
Propoxyphene
Methadone
Sedatives
Etchlorvynol
Chlordiazepoxide
Anticonvulsants
Diphenylhydantoin
Carbamazepine
Diuretics
Hydrochlorothiazide
Major Tranquilizers
Haloperidol
Fluphenazine
Antiarrhythmics
Amiodarone
Lidocaine
Tocainide
Procainamide
B adrenergic blockers
Practolol
Propranolol
Pindolol
Miscellaneous
Gold salts
Penicillamine
Isoniazid
Colchicine
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Table 2
Risk factors predisposing to development of
drug induced pulmonary diseases
Risk Factor
Cumulative dose
Unit dose:
Route of Administration:
Frequency of Administration:
Oxygen therapy:
Radiotherapy:
Other Drug therapy:
Age:
Previous Pulmonary diseases:
Blood component transfusions :
Renal failure:
Steroid tapering or
adrenalectomy:
Pulmonary angiography:
Drug(s) Implicated
Bleomycin, carmustine (BCNU),
amiodarone
Amiodarone, Heroin, Proproxyphene
methadone, Ethchlorvynol,
Chlordiazepoxide, Haloperidol,
Colchicine, Imipramine.
Bleomycin
Methotrexate
Bleomycin, Mitomycin,
Cyclophosphamide, Nitrofurantoin
Bleomycin, Busulfan, Mitomycin
Bleomycin, BCNU,
Cyclophosphamide, Mitomycin,
Methotrexate, Vinca alkaloids
Bleomycin
BCNU, Amiodarone
Mitomycin, Amphotericin
Bleomycin
Methotrexate
Amiodarone
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Table 3
Drugs that cause pneumonitis/fibrositis
Cancer Chemotherapeutlc agents
Bleomycin
Mitomycin
Busulfan
Neocarzinostatin
Cyclophosphamide
Chlorambucil
Melphalan
Carmustine (BCNU)
Semustine (Methyl CCNU)
Lomustine (CCNU)
Chlorozotocin
Methotrexate
Drugs that cause hypersensitivity pneumonitis
Bleomycin
Methotrexate
Procarbazine
Azathioprine
Mercaptopurine
Sulfasalazine
Nitrofurantoin
Diphenylhydantoin
Carbamazepine
Chlorpropamide
Imipramine
Isoniazid
Sulfadimethoxine
Other Drugs
Nitrofurantoin
Sulfasalazine
Amiodarone
Tocainide
Gold salts
Penicillamine
Table 4
Paraaminosalicyclic acid
Penicillin
Cromolyn
Dantrolene
Methylphenidate
Mephenesin carbamate
Hydralazine
Mecamylamine
Ampicillin
Febarmate
Salazopeyrin
Naproxen
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Table 5
Drugs that cause non -cardiogenic pulmonary oedema
Cancer chemotherapeutic Drugs Other Drugs
Mitomycin
Cyclophosphamide
Methotrexate
Cytosine arabinoside
VM - 26
Amphotericin
Heroin
Propoxyphene
Methadone
Ethchlorvynol
Chlordiazepoxide
Haloperidol
Lidocaine
Terbutal ine
Ritodrine
Isoxsuprine
Imipramine
Colchicine
1.
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